Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

News and Trends 6 Oct 2016

New UK Hero Will Fight Against Non-Small Cell Lung Cancer

Achilles Therapeutics was born yesterday in the UK with a €15M funding round. The company will focus on the development of personalized neo-antigentherapies for non-small lung cancer. The newborn Achilles Therapeutics made its debut yesterday with a splashy fundraising round and a licensing agreement. The startup has exclusive rights to develop and commercialize any neo-antigen technology that […]

October 6, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Oct 2016

€365M deal for a Danish ‘DNA barcode’ Drug Screening Platform

The giant Amgen has offered Nuevolution €365M to develop oncology and neuroscience drugs. The small Danish Biotech claims to count with an unprecedented drug discovery platform that can screen billions of compounds way faster and at a lower cost than the big players. Despite its small size, Nuevolution is experienced in collaborating with big Pharma like Merck, Novartis, […]

October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Oct 2016

New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira

New results from a Phase III trial show that guselkumab, an antibody therapy for the autoimmune disease plaque psoriasis, is performing better than the number one best-seller drug Humira (adalimumab) from AbbVie. The new drug is expected to be commercially available as early as 2018. Since MorphoSys licensed guselkumab to Janssen Biotech, in 2007, the drug has been performing […]

October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Oct 2016

One Step Closer to an HIV Cure That Can Eliminate the Latent Virus

HIV has completely disappeared from the blood of a patient in clinical trials. The new HIV treatment that can target the virus even in its dormant state by activating latent infected cells and could possibly become the first HIV cure available. These initial results show that the new therapy, developed in the UK, may be effective in curing HIV. One of 50 […]

October 4, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Oct 2016

Researchers Find New Weak Spots to Develop an HIV Cure

Last week we published a thorough review on current approaches for an HIV cure, which may be available as soon as 2020. Academia has come up with two additional strategies that could make a huge difference in the study of HIV. HIV affects 36.7 million people in the world and caused 1.1 million deaths last year. Plenty of resources […]

October 3, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Oct 2016

This Belgian Bioartist is deconstructing Chicken Evolution

Koen Vanmechelen is an artist that works in the intersection of art and research. His art focuses on exploring biocultural diversity… using chickens! Koen Vanmechelen‘s core artistic work is the Cosmopolitan Chicken Project (CCP), in which the artist cross-breeds chickens from all around the world. The aim: to create the ultimate chicken that will combine genes from […]

October 1, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 09 29 at 4.53.52 PM e1475160985987

News and Trends 30 Sep 2016

Tailored Cancer Vaccines? NousCom is working on it!

We aren’t leaving Switzerland yet! We took a scenic train to Basel in order to meet nousCom, a very young biotech developing cancer vaccines. City: Basel, Switzerland Founded: 2015 Employees: unknown Financial Data: €12M raised in series A Mission: NousCom is a Biotech that develops next generation cancer vaccines with patient- and tumor-specific antigens. Their vaccines combine viruses […]

September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 30 Sep 2016

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

GeNeuro is developing a unique treatment for multiple sclerosis. We interviewed Miguel Payro, the company’s CFO, who explained its advantageous position against big pharma. GeNeuro raised €33M in its Euronext IPO in April and is currently competing against giants like Novartis and Biogen. Despite 2016’s dubious honor as “the worst year for IPO in 20 years”, this Switzerland-based company has managed to go […]

September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 29 Sep 2016

Boehringer buys a €210M ticket to Virus-based Immuno-Oncology

Boehringer Ingelheim has signed a deal with ViraTherapeutics, an Austrian start-up that focuses on the development of oncolytic virus therapies. If everything goes well, the big Pharma could acquire the Biotech start-up after completion of Phase I trials. Boehringer Ingelheim has its eye on ViraTherapeutics’ oncolytic virus platform. The young Biotech’s technology establishes a novel treatment approach that […]

September 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Sep 2016

Debunking the Immuno-Oncology Hype: is it as good as it sounds?

CAR-T therapies have gained plenty of attention lately by promising to end cancer with a one-off treatment. But all that glitters is not gold; experts remind us it is important to be critical about the immuno-oncology hype. Immuno-oncology has become all the rage lately, and the hype has led to some major investments, acquisitions, deals and partnerships. It seems […]

September 29, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Sep 2016

Biotech is one of the biggest Employers in Europe

As part of the European Biotech Week, EuropaBio shared yesterday a study revealing that Industrial Biotech has created 486,000 full-time jobs and contributes €31.6B to the EU. This new data emphasizes the huge role that Biotech plays on the continent’s economy. The biotech industry was in the spotlight this week at the European Parliament, where the report was presented, and it […]

September 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Sep 2016

The Future of Portugal as explained by Microorganisms

Microbiology makes its mark at the first edition of the London Design Biennale taking place in Somerset House. Portugal’s exhibition by Marta de Menezes uses bacteria and viruses to create changing art that represents the future direction of the country. With the common topic “Design by Utopia“, 30 nations have interpreted utopic and dystopic futures using art to […]

September 24, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us